|
KMID : 0363220150530080617
|
|
Korean Journal of Dermatology
2015 Volume.53 No. 8 p.617 ~ p.622
|
|
|
Efficacy and Safety of Ustekinumab in the Treatment of Moderate to Severe Psoriasis in Korea
|
|
Park Sung-Min
Kim Jeong-Min
Kim Gun-Wook
Mun Je-Ho
Song Margaret
Kim Hoon-Soo
Ko Hyun-Chang
Kim Moon-Bum
Kim Byung-Soo
|
|
|
Abstract
|
|
|
Background: Ustekinumab, a fully human monoclonal immunoglobulin antibody that targets the P40 subunit shared by interleukin (IL)-12 and IL-23 has emerged as a promising treatment for moderate to severe psoriasis. However, to date, there are no ‘clinical practice setting’ data on ustekinumab in Korean patients with psoriasis.
Objective: To assess the clinical efficacy and safety of ustekinumab in Korean patients with psoriasis.
Methods: Prospective data were gathered during the follow-ups of 34 consecutive chronic plaque psoriasis patientstreated with ustekinumab for a minimum of 16 weeks at a single referral center. Patients’ demographics, Psoriasis Area Severity Index (PASI) score, Physicians’ Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.
Results: The mean PASI score significantly decreased after the first administration of ustekinumab (paired t-test, p＜ 0.05). Twenty-one of 34 patients (61.8%) had obtained near-complete clearance (PASI 90) upon the last follow-up visit. No unexpected adverse events other than herpes zoster and elevated liver enzymes were observed.
Conclusion: Ustekinumab can be of benefit in the treatment of Korean psoriasis patients, as it was associated with a rapid and satisfactory response and was well tolerated.
|
|
|
KEYWORD
|
|
|
Clinical setting, Efficacy, Psoriasis, Safety, Ustekinumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|